Joe Duarte

Dr. Joe Duarte has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

 It’s time to give thanks and take profits on the Texas Instruments January 70 call option. I recommended the the option along with the stock in the September issue of Breakthrough Tech Profits.  And while the stock has done well- up nearly 11% as of the close on 11/22/16 –… Read More

Trumpcare is coming but its makeup, its directives, and its effects are a big unknown. Thus, at least in the early innings, the use of options as a trading vehicle to capitalize from the movement in stocks that will likely be affected by this new dynamic is sensible. In my… Read More

It’s time to sell this straddle.  I recommended the trade as a hedge against the election which Wall Street has surprisingly handled fairly well.  Because of the relatively low volatility in the market after the election and the slow and steady move to the upside, the large move required to… Read More

Shares of Airgain (NSDQ: AIRG) have exploded to the upside after a much better than expected earnings report released last week.  I am recommending taking profits on the position with a near 50% gain in the shares as of the open of trading on November 15.  Shares were initially… Read More

Certain biotech stocks, such as Gilead are likely to respond to changes in the healthcare system brought about by Trumpcare.  This trade has yet to develop fully, yet has an excellent chance to deliver a significant profit once the stock breaks up or down.  Read More

Shares of Airgain (NSDQ: AIRG), a leading provider of embedded premium high-performance antennas for electronic devices, rallied after it reported well-above expected earnings for its quarter ending on September 30, 2016. The company reported $12.4 million in sales, an 87% improvement over the prior year while delivering 16 cents per… Read More

The rising uncertainty about a healthcare system under President Trump is starting to sink in and the market seems to be in sell mode for pharmaceutical companies. So it’s a good time to sell Opko Health (NSDQ: OPK), a company specializing in hormone treatments and kidney dialysis related treatments, with… Read More

It’s time to close out the Anthem straddle. The trade has delivered an excellent gain and we don’t want to let the time premium and the upcoming weekend erode into our profit.SELL to close Anthem December 16, 120 Strike Price Put (ATNM121616P120)  Bought on 8/29/16 at $5.15. Closing price on 11/10/16… Read More

The post-election rally seems to have some short-term legs and the healthcare stocks are putting on quite a show. The early indications suggest that money is aggressively flowing into the health insurance companies. As a result, a change of tactics is called for.I recommend the sale of the Johnson &… Read More